Amedisys Inc (AMED) Earns Buy Rating from SunTrust Banks, Inc.
SunTrust Banks, Inc. restated their buy rating on shares of Amedisys Inc (NASDAQ:AMED) in a research note issued to investors on Monday morning. SunTrust Banks, Inc. currently has a $60.00 target price on the health services provider’s stock.
Several other brokerages have also weighed in on AMED. Oppenheimer Holdings, Inc. reaffirmed a buy rating and set a $60.00 target price on shares of Amedisys in a research note on Friday, September 15th. BidaskClub lowered shares of Amedisys from a hold rating to a sell rating in a research note on Saturday, August 5th. Bank of America Corporation initiated coverage on shares of Amedisys in a research note on Monday, August 21st. They set a neutral rating and a $55.00 target price for the company. Robert W. Baird reaffirmed a hold rating and set a $50.00 target price on shares of Amedisys in a research note on Wednesday, October 4th. Finally, Mizuho lowered shares of Amedisys from a buy rating to a neutral rating and set a $50.00 target price for the company. in a research note on Wednesday, July 26th. Seven investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of Hold and an average target price of $56.20.
Shares of Amedisys (NASDAQ:AMED) opened at 48.63 on Monday. The stock has a 50 day moving average of $51.93 and a 200 day moving average of $55.20. Amedisys has a 12-month low of $34.58 and a 12-month high of $65.91. The company has a market cap of $1.65 billion, a price-to-earnings ratio of 41.56 and a beta of 0.87.
Amedisys (NASDAQ:AMED) last announced its earnings results on Wednesday, July 26th. The health services provider reported $0.62 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.50 by $0.12. The company had revenue of $378.80 million during the quarter, compared to analyst estimates of $380.80 million. Amedisys had a net margin of 2.70% and a return on equity of 13.71%. Amedisys’s revenue was up 5.0% compared to the same quarter last year. During the same quarter last year, the firm posted $0.42 earnings per share. Equities research analysts predict that Amedisys will post $2.21 earnings per share for the current fiscal year.
In other Amedisys news, Director Bruce D. Perkins purchased 2,000 shares of Amedisys stock in a transaction dated Thursday, August 3rd. The shares were acquired at an average price of $46.60 per share, with a total value of $93,200.00. Following the completion of the transaction, the director now owns 15,825 shares of the company’s stock, valued at $737,445. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider David B. Pearce sold 1,000 shares of the stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $50.00, for a total transaction of $50,000.00. Following the sale, the insider now directly owns 10,488 shares in the company, valued at approximately $524,400. The disclosure for this sale can be found here. 2.00% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently modified their holdings of the company. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Amedisys during the second quarter worth about $591,000. Piedmont Investment Advisors LLC acquired a new stake in shares of Amedisys during the second quarter worth about $380,000. Castleark Management LLC acquired a new stake in shares of Amedisys during the second quarter worth about $3,674,000. The Manufacturers Life Insurance Company lifted its position in shares of Amedisys by 1.9% during the second quarter. The Manufacturers Life Insurance Company now owns 22,348 shares of the health services provider’s stock worth $1,404,000 after purchasing an additional 410 shares in the last quarter. Finally, State Street Corp lifted its position in shares of Amedisys by 3.9% during the second quarter. State Street Corp now owns 723,786 shares of the health services provider’s stock worth $45,461,000 after purchasing an additional 26,888 shares in the last quarter. 96.55% of the stock is currently owned by institutional investors and hedge funds.
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.